Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (1382)	5/22/1998 12:08:00 AM
From: D.Right	Read Replies (2) \| Respond to of 2173

Dear Arnie: I did go to the meeting. It was a good one, no big news though (nobody is expecting one anyway). My general impression is they are going to sign a deal for sure. The other option of waiting for european trial, get good result, boost stock price, offer more shares and then market the drug by themselves is very unlikely. The deal may take a little while though. They sure want to cut a deal like auction Kennedy's golf club but not like to do a garage sale. Good thing is there are multiple insulin makers out there. My bet will be one of the insulin makers will sign with them. Mr. Cook said he would prefer someone international, big and with a lot of money to throw around. IMO, the longer they hold, the better a deal they may get, although that does give them more risk with very low level of cash left. They did say something new. 1. Pramlintide did help reducing hypoglycemia risk in the steady insulin groups from last trial IIIs. Again, the number of patients is not enough to do good statistics. 2. The program to provide pramlintide to trial patients after they finished clinical III has stopped for cost reasons. 3. Some detailed number on the cholesterol improvement, but I did not get all the numbers during presentation. 4. Reserve money anyway they can to push pramlintide only. They stopped most activities of all other drug candidate even when the exendin data are very good and ready to get into human trials. 5. More insulin and pramlintide mix trials will wait until they get the eurapean data to begin and will be open label trail only. 6. Patients enrollment for the two US clinicals is on schedule and should finish soon. That's pretty much what I remembered. Most important impression is they will sign a deal for sure, no need to worry they will run out of cash. The only question is how good the deal will be. There is hope, at least, for a great deal. Good Night. D.Right